Variants in patatin-like phospholipase domain-containing 3 (PNPLA3; rs738409), transmembrane 6 superfamily member 2 (TM6SF2; rs58542926), and membrane bound O-acyltransferase domain containing 7 (MBOAT7; rs641738) are risk factors for the development of alcohol-related cirrhosis. Within this population, PNPLA3 rs738409 is also an established risk factor for the development of hepatocellular carcinoma (HCC). The aim of this study was to explore possible risk associations of TM6SF2 rs58542926 and MBOAT7 rs641738 with HCC.
IntroductIon
The incidence of hepatocellular carcinoma (HCC) is increasing and it is now the fifth most frequent cancer and third most frequent cause of cancer-related mortality world-wide [1] [2] [3] . In western countries, the presence of cirrhosis is a major risk factor for the development of HCC, which only rarely evolves in noncirrhotic livers [1, 4, 5] . Persistent high-alcohol consumption is the leading cause of cirrhosis in these areas. The prognosis of patients with HCC is grave as it is often detected only when it reaches an advanced stage.
Between 5 to 15% of patients with alcohol-related cirrhosis are potentially at risk for developing HCC with a 5-year cumulative risk of around 8% [1] . Identifying disease-modulating factors, which render some individuals more susceptible to its development than others, is clearly of major importance as it would allow more specific targeting of surveillance programmes. Older age, male sex, and more advanced liver disease at presentation are known to be important predictors, but do not account for more than a small proportion of the observed risk variance. Mounting evidence suggest that host genetic factors may significantly modify the risk for developing HCC. Thus, identifying these factors in patients with alcohol-related cirrhosis is clearly of major importance.
A single nucleotide polymorphism (SNP), rs738409 C > G, in patatin-like phospholipase domain-containing 3 (PNPLA3) is an established risk factor for the development of alcohol-related cirrhosis in Caucasian populations [6] [7] [8] [9] . A recent meta-analysis of individual patient data from candidate gene studies has shown that the PNPLA3 rs738409 G allele is also an independent risk factor for the development of HCC in this patient population [10, 11] . Recently, variants in two further genes viz. rs58542926 in transmembrane 6 superfamily member 2 (TM6SF2) and rs641738 in membrane bound O-acyltransferase domain containing 7 (MBOAT7) were identified as risk factors for the development of alcohol-related cirrhosis in a genome-wide association study (GWAS) [12] . Although a proportion of the cases included in the GWAS had developed HCC, the numbers were too small to allow a meaningful subset analysis. However, data from two candidate gene studies support a role for variants in or linked to TM6SF2 as potential risk factors for HCC development. Thus, Nischalke et al. found a significant association between rs2228603, in the gene coding for neurocan (NCAN), and the development of HCC in people with alcohol-related cirrhosis [13] ; this variant is in close linkage disequilibrium with TM6SF2 rs58542926. Falleti et al. genotyped TM6SF2 rs58542926 in 226 cases with alcohol-related cirrhosis, of whom 75 (33%) had HCC [14] . The rs58542926 T/*genotype was more frequent in those cases with HCC (adjusted odd ratio [OR] 2.57; p = 0.035). They found no interaction between PNPLA3 rs738409 and TM6SF2 rs58542926 and HCC risk. These preliminary findings need to be further explored. No studies have been undertaken, to date, to explore the possible risk association between MBOAT rs641738 and the development of HCC in patients with alcohol-related cirrhosis.
The aim of the present study was to determine whether variants in PNPLA3, TM6SF2, and MBOAT7 are the risk factors for the development of HCC, alone or in synergy, in a large, well-characterized population of people with alcohol-related cirrhosis.
Methods

Patient cohorts
For purposes of this study, cases were defined as people with alcohol-related cirrhosis and HCC, and controls as people with alcohol-related cirrhosis but without evidence of HCC. Cases and controls were recruited from Hepatology centers across Europe (Switzerland, Germany, United Kingdom) and were of selfreported Swiss German/German/British/Irish ancestry (Supplementary Table 1 ).
The diagnosis of alcohol-related cirrhosis was established as described previously [12] ; it was based on a history of prolonged, sustained alcohol intake of a minimum of 40 g/day in women and 60 g/day in men together with histological examination of liver tissue or compatible historical, clinical, laboratory, radiological, and endoscopic features. Patients were excluded if they had any other potential cause of liver injury, specifically if they were positive for hepatitis B surface antigen (HBsAg), anti-hepatitis C immunoglobulin G (anti-HCV IgG), anti-nuclear antibodies (ANA) (titer > 1:80), or anti-mitochondrial antibodies (titer > 1:40). Patients with elevated serum ferritin concentrations and a transferrin saturation of >50% underwent high iron Fe (HFE) genotyping and were excluded if homozygous to the C282Y variant. Likewise, patients with a serum ceruloplasmin of <20 mg/dl (0.2 g/dl) or serum alpha-1 antitrypsin of <70 mg/dL (13 µmol/L) were further investigated and excluded if necessary. Patients were also excluded if morbidly obese but not if overweight.
The diagnosis of HCC was based on histological examination of tumor tissue or evidence on imaging, preferably using two modalities of lesions that are hypervascular in the arterial phase with washout in the portal venous or delayed phases [15] . The severity of underlying alcohol-related liver injury was assessed using Pugh's modification of the Child's grading system [16] .
DNA preparation and genotyping
DNA was prepared using the FlexiGene chemistry (Qiagen, Hilden, Germany). For preparation of genotyping, DNA samples were evaluated by gel electrophoresis and adjusted to 20-30 ng/µl DNA content using the Picogreen fluorescent dye (Molecular Probes -Invitrogen, Carlsbad, CA, USA) on a robotic platform with TECAN liquid-handling equipment. One microliter of genomic DNA was amplified with the GenomiPhi (Amersham, Uppsala, Sweden) whole-genome amplification kit and fragmented at 99 °C for 3 min. The 5 ng of DNA were dried overnight in TwinTec hardshell 384 well plates (Eppendorf, Hamburg, Germany) at room temperature. Genotyping of PNPLA3 rs738409 (Assay ID HCV7241_10), TM6SF2 rs58542926 (Assay ID HCV89463510_10), and MBOAT7 rs641738 (Assay ID HCV8716820_10) was performed using TaqMan ® SNP Genotyping Assays and chemistries (Applied Biosystems, Foster City, CA, USA) on an automated platform with TECAN Freedom EVO and 384 well TEMO liquid-handling robots (TECAN, Männedorf, Switzerland) as described before [12] .
All process data were logged and administered with a databasedriven LIMS. Reactions were completed and read in a 7900 HT TaqMan sequence detector system (Applied Biosystems, Foster City, CA, USA). The amplification reaction was carried out with Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcino...
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Statistical analysis
Statistical analysis of data were performed using SPSS v.24.0 (IBM Corp., Armonk, NY, USA). Comparisons of frequencies of genotypes at the three loci were performed on 3 × 2 contingency tables between the cases and the controls. Genotypic and allelic tests of association were performed using χ 2 statistics or Fisher's exact tests as appropriate. For all tests, nominal p-values are reported. The association between SNPs and the risk of HCC was estimated by calculating the beta coefficients and their standard errors using logistic regression models adjusted for age, sex, BMI, and diabetic status, assuming log-additive genetic effects. The interactions between polymorphic loci were examined by testing the allelic and the genotypic interaction terms in the logistic regression models. Results are expressed as odds ratios (OR) and 95% confidence intervals (CI).
Population-attributable fraction
The population-attributable fraction (PAF) provides an epidemiological estimate of the proportion with the disorder, which is attributable to the risk factor. Thus, it is an estimate of how much lower the frequency of HCC would be in the patients with alcohol-related cirrhosis, if the risk genotype(s) were eliminated from the population.
The PAF was estimated for heterozygous and homozygous carriage using the formula
where x = (1-p)2 + 2p(1-p)OR1 + p2OR2; p is the allele frequency in alcohol-related cirrhosis, and OR1 and OR2 are the ORs associated with hetero and homozygosity adjusted by sex, age, body mass index (BMI) and type 2 diabetes mellitus, respectively [17] .
Combined PAF estimates were calculated based on the individual PAFs for each associated SNP, assuming no multiplicative interaction among the SNPs [17] .
Ethics
The study was approved by the ethics committees of the participating institutions; all included subjects provided written informed consent prior to inclusion into the study.
results
The cases were significantly older than the controls; proportionately more were male, overweight and had comorbid type 2 diabetes mellitus (Table 1) . However, the cases were significantly less likely to have decompensated liver disease ( Table 1) .
Genotyping was completed for all three SNPs with call-rates greater than 95%; there were significant differences in the genotyping call-rates between cases and controls, but the distributions of the missing data were random and not skewed. All markers followed Hardy-Weinberg equilibrium (cutoff HWE P > 0.05) in both the cases and the controls ( Table 2) .
Allelic and genotypic associations of PNPLA3 rs738409 with HCC in alcohol-related cirrhosis were highly significant (P allelic = 3.64 × 10 −20
, P geno = 6.14 × 10
−18
). The odds ratio (OR) for homozygous carriers of the risk allele PNPLA3 rs738409 G was 3.26 (95% CI: 2.50-4.25) compared to the risk in heterozygous carriers of 1.70 (95% CI: 1.37-2.10). The allelic and genotypic associations of TM6SF2 rs58542926 with HCC in alcohol-related cirrhosis were also highly significant at P allelic = 8.93 × 10 −7 and P genotypic = 7.74371 × 10
, respectively. The OR for homozygous carriage of the risk allele TM6SF2 rs58542926 T was 3.32 (95% CI: 1.76-6.24), while the OR for heterozygous carriage was 1.46 (95% CI: 1.15-1.84). In contrast, neither heterozygous nor homozygous carriage of the MBOAT7 rs641738 T allele was associated with HCC risk; the allelic and genotypic levels of significance were P allelic = 0.639 and P genotypic = 0.676, respectively, while the corresponding ORs for homozygous and heterozygous carriage of the T allele were 1.07 (95% CI: 0.83-1.38) and 0.96 (95% CI: 0.77-1.20), respectivey.
The minor allele frequencies (MAF) of all three loci in the controls in the present study were in line with those observed in the previous GWAS in alcohol-related cirrhosis [12] , but the frequencies of PNPLA3 rs738409 G and TM6SF2 rs58542926 T were higher in the cases. The MAF for MBOAT7 rs641738 T was similar in cases and controls.
The robustness of the association of PNPLA3 rs738409, TM6SF2 rs58542926 and development of HCC was confirmed after the adjustment for other known risk factors viz. age, sex, BMI and type 2 diabetes mellitus ( Table 3 ). The lack of association with MBOAT7 rs641738 did not change following adjustment for these confounders.
The association of PNPLA3 rs738409 and TM6SF2 rs58542926 with HCC was consistent across separate cohorts from Switzerland, Germany, Britain, and Ireland, as was the lack of association with regard to MBOAT7 rs641738 (Supplementary Figures 1A-C) .
The PAF% for PNPLA3 rs738409 was 43.5% and for TM6SF2 rs58542926 was 11.4%, yielding a combined PAF% for both risk loci of 49.9% ( Table 4) .
The proportion of cases and controls who carried either no, one out of two, or both risk variants in PNPLA3 and TM6SF2 illustrated the aggregated risk due to co-carriage of risk loci (Fig. 1) . Thus, only 10% of the controls and approximately 20% of the cases carried both risk alleles.
dIscussIon
Elucidating the genetic background of chronic liver diseases is important as it will enable an individual's risk to develop progressive liver damage to be assessed more precisely, and will allow greater insight into the currently unknown molecular aspects of the underlying pathophysiology. Of particular importance is the definition of the risk factors predisposing an individual with a priori cancer risk, i.e., cirrhosis, to the development of lifethreatening malignancy, particularly if defining the risk factors would allow the development of a strategy for more individualized screening and targeted prevention.
The present study provides data of the largest cohort of patients with HCC and a background of alcohol-related cirrhosis under- Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcino...
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The American Journal of GastroenteroloGy taken to date and provides further confirmation that the PNPLA3 rs738409 G allele is the strongest independent genetic risk factor for HCC in this patient population [10, 11] . The present analysis further expands the panel of genetic risk factors for HCC to include TM6SF2 rs58542926, albeit with lesser effect as reflected by its lower OR and PAF%. It also showed a lack of association with MBOAT7 rs641738. There is only limited information on the possible risks associated with carriage of TM6SF2 rs58542926 and MBOAT7 rs641738 and the development of HCC, with which to compare the findings of the present study. Nischalke et al. in a relatively small, multicentre study found a significant risk association between carriage of rs2228603 in neurocan (NCAN) and the development of HCC in patients with alcohol-related cirrhosis [13] . This genetic variant had been linked with the development of hepatic steatosis in a previous GWAS in non-alcoholic fatty liver disease (NAFLD) [18] . Subsequent genetic fine-mapping showed that NCAN rs2228603 lies within 50 kb and is in strong linkage disequilibrium with TM6SF2 rs58542926 [19] . A subsequent exome-wide analysis conclusively identified TM6SF2 rs58542926 as the more likely risk factor for progressive NAFLD in this genomic region [20] . Falleti et al. [14] analyzed a cohort of 511 patients with cirrhosis of mixed etiology, of whom 101 had HCC, and found an association between the risk of developing HCC and carriage of the TM6SF2 rs58542926 T allele in the 226 patients with alcohol-related cirrhosis (Adjusted OR = 2.57; p = 0.035). They found no interaction between PNPLA3 rs738409 and TM6SF2 rs58542926 in relation to HCC risk.
A recent candidate gene-association study from Italy and the UK investigated the association between variants within MBOAT7 and HCC in a mixed cohort of patients with NAFLD, chronic hepatitis C, and alcohol-related liver disease, the majority of whom did not have cirrhosis [21] . The authors reported a significant association between MBOAT7 rs641738 and HCC in non-cirrhotic patients with NAFLD, but only in the Italian cohort. The findings were not however replicated in a validation cohort of UK patients. The reason for this discrepancy likely relates to the fact that development of HCC in non-cirrhotic patients and people with viralrelated liver disease in western countries is very rare and hence the number of cases was small. Thus, the inability of these workers to replicate their findings may reflect the inconsistency of the chosen phenotypes studied and/or low statistical power.
The lack of association between HCC risk and MBOATrs641738 is further supported by a recent candidate gene study in people with chronic hepatitis C, which demonstrated that the influence of this variant is restricted to the transition from absence of fibrosis to mild fibrosis [22] . In this same study, no difference was observed in the MAF of MBOAT7rs641738 in a small subgroup of 75 people with HCV-related HCC within an entire cohort of 1706 indicating a lack of statistical power. However, the present study was adequately powered to detect an allelic odds ratio of 1.18 with 80% power, and hence the finding of no association between MBOAT7 rs641738 and the development of HCC in alcohol-related cirrhosis is robust [23] and was consistent across all study subpopulation (Supplementary Figure 1C) .
In the present study, carriage of risk alleles in PNPLA3 and TM6SF2 accounted for almost 50% of the population-attributable genetic risk for the development of HCC in patients with alcohol-related cirrhosis. The combined PAF% is usually lower than the sum of each individual PAR%, but not in this instance. The odds ratio was, in fact, greater than 3 for homozygous carriage and ~1.5 for heterozygous carriage for both variants, and hence surprisingly high for a germline genetic risk factor in a complex disorder.
The possibility that these genetic markers could be included in the stratification score to identify patients at high risk for HCC has to be considered. Hypothetically, screening intervals could be tailored according to the genetic signature in a given patient, applying longer intervals in those minimal inherited predisposition, and shorter periods for those who carry both risk alleles. However, any such proposals would need to be tested in prospective surveillance studies designed to assess the possible patient benefit.
Anstee et al. [24] have recently looked at the clinical utility of PNPLA3 genotyping for stratifying the risk for developing HCC in patients with NAFLD in a reanalysis of the data published by Liu et al. [25] . They found that use of PNPLA3 genotyping alone to positively predict the risk of developing HCC was unlikely to be tenable. However, the negative predictive value (NPV) was substantially greater, suggesting that genotyping this SNP might have utility for selecting those individuals who are least likely to develop HCC and therefore, least likely to benefit from surveillance. Using a similar approach, the diagnostic test performance for PNPLA3 and TM6SF2 genotyping for the detection of HCC risk in the present study cohort showed a NPV of 72.5% for the combination PNPLA3 rs738409 GG and TM6SF2 rs58542926 *T. Based on these figures, a schema for individual screening intervals is proposed with the caveat that any adoption must be subjected to appropriate prospective evaluation ( Table 5) .
The distinct genetic profiles of the alcohol-related cirrhosis risk genes with regards to liver carcinogenesis also have intriguing functional implications. The PNPLA3 rs738409 GG variant is considered a loss-of-function mutation, and as such is less able to hydrolyze triglycerides from lipid droplets leading to lipid trapping in hepatocytes and increased lipotoxicity. Since progression of fibrosis is only weakly associated with the degree of steatosis [26] , additional effects beyond mere lipid accumulation are suspected. Thus, PNPLA3 rs738409 has been functionally linked to increased levels of circulating pro-inflammatory mediator intracellular adhesion molecule 1 (ICAM-1) [27] , which is also overexpressed in human HCC stem cells and circulating HCC tumor cells [28] . Furthermore, in patients with NAFLD PNPLA3 rs738409 G allele was found to be associated with decreased levels of Fig. 2 Putative functions of proteins encoded by PNPLA3, TM6SF2, and MBOAT7. All proteins encoded by the three genes are enzymes related to lipid/ fatty acid turnover are expressed in the liver tissue. The functional link to hepatocarcinogenesis is as yet unknown. PNPLA3 [1] is an enzyme with both triacylglycerol lipase and acylglycerol O-acyltransferase activities and plays an important role in the balance of energy usage/storage in adipocytes, hepatocytes, and likely, hepatic stellate-cells [9, 34] . Expression of PNPLA3 protein and mRNA increases the following food intake. The polymorphic variant (PN-PLA3 rs738409 G) is a loss-of-function mutation, in which structural alteration of the substrate-binding groove leads to lower substrate accessibility, and thus less triglyceride hydrolysis [35] . Also, the mutant variant rs738409 G, which locates on lipid droplets, evades proteasomal degradation by disrupting ubiquitylation [36] . Consequently, the mutant PNPLA3 variant accumulates resulting in impaired triglyceride mobilization [36] . TM6SF2 [2] is only incompletely characterized functionally, but appears to modulate hepatic lipoprotein export and lipidation of very low-density lipoproteins (VLDL). A functional link between TM6SF2 and the microsomal triglyceride transfer protein (MTTP) jointly regulates the assembly and secretion of VLDL and triglycerides (TG) from liver cells into the bloodstream. The polymorphic variant of the TM6SF2 gene (rs58542926 T) encodes a loss-of-function TM6SF2 protein, which impairs VLDL export and, thus, increases intracellular lipids, but decreases the circulating serum VLDL, LDL, and triglyceride levels. These opposing functional differences result in distinct risk effects on steatosis and liver fibrosis (increased with variant rs58542926 T) [31] and on cardiovascular risk (increased with wild type rs58542926 C) [32] . MBOAT7 [3] is a lysophosphatidylinositol acyltransferase, and as such is involved in membrane phospholipid remodeling. it catalyzes the transfer of acyl-CoA to lysophosphatidylinositol (LPi) with a strong propensity for arachidonoyl-CoA as the acyl donor [37] . Consequently, it may regulate the mechanisms by which pro-inflammatory free arachidonic acid (ArA) and eicosanoid levels are regulated. increased availability of ArA leads to inflammatory signaling by prostaglandins and leukotrienes, which are potent chemoattractants of inflammatory cells. The MBOAT7 rs641738 T allele leads to lower hepatic MBOAT7 protein expression and changes in plasma phosphatidylinositol profiles consistent with a loss of function variation [38] Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcino...
The American Journal of GastroenteroloGy adiponectin, which has important anti-inflammatory, anti-fibrotic, and anti-carcinogenic properties [29] . Recent data in cell culture and mice xenografts also suggest an effect of PNPLA3 rs738409 on the activation of the interleukin (IL)-6-Janus kinase (JAK2)/Signal Transducers and Activators of Transcription (STAT3) pathway via fatty acid-mediated inflammation [30] . Therefore, functional studies linking the 'lipid droplet disease', caused by PNPLA3 malfunction, to cancer may likely unravel interesting insights into the pathophysiology of HCC.
While the promoting effect of PNPLA3 rs738409 on HCC evolution remains incompletely understood, even less is known about the possible role of genetic variation of TM6SF2 in this process. TM6SF2 is involved in the assembly and secretion of very lowdensity lipoproteins, similar to microsomal triglyceride transfer protein (MTTP), and thus a loss-of-function mutation would be compatible with lipid accumulation in hepatocytes. Accordingly, Sookoian et al. [31] performed allele-specific expression analyses of cDNA isolated from liver tissue from patients with NASH and confirmed that the expression levels of the rs58542926 T allele are reduced to about 56% to that of the wild-type C allele. These findings suggest that carriage of the TM6SF2 T risk allele is associated with decreased hepatic gene and protein expression, leading to a loss of function similar to the mutant PNPLA3 variant. In turn, the wild-type TM6SF2 protein has been associated with increased serum VLDL levels and an elevated cardiovascular risk [32] , but less liver injury [33] . Whether and how there may be cross-talk between TM6SF2 and signaling pathways pertinent for HCC development beyond mere intracellular lipid accumulation, lipotoxicity remains to be elucidated.
The putative functions of the three proteins: PNPLA3, TM6SF2, and MBOAT7, as well their polymorphic variants are illustrated in Fig. 2 .
This study has its limitations, primarily the fact that it was undertaken retrospectively and was restricted to caucasian people with alcohol-related cirrhosis. Thus the findings do not necessarily define the genetic risks for HCC development in people with liver disease of other aetiologies or to other ethnic groups. However, it also has its strengths, including the size of the study population, and the fact that similar effect sizes were observed across component geographical cohorts. Thus, the presented data provides robust evidence for a strong effect of PNPLA3 rs738409 on HCC risk in patients with alcohol-related cirrhosis. In addition, TM6SF2 rs58542926 is identified and confirmed as a significant host genetic risk factor for HCC, while MBOAT7 rs641738 is not. In combination, PNPLA3 rs738409 and TM6SF2 rs58542926 account for almost 50% of the population-attributable risk for the development of HCC, and thus, should be evaluated further for stratification of patients at risk in the screening programs. In addition, sight should not be lost of the fact that a significant proportion of the genetic variance still remains to be identified.
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Study Highlights
WHAT IS CURRENT kNOWLEDGE ✓ ✓ the gene variant PNPLA3 rs738409 is an established risk factor for the development of alcohol-related cirrhosis and for the subsequent development of hepatocellular carcinoma (hcc) within this population. ✓ ✓ two other risk variants, TM6SF2 rs58542926 and MBOAT7 rs641738, are associated with the development of alcohol-related cirrhosis, but their role in the subsequent development of hcc is unclear.
